149 related articles for article (PubMed ID: 32556682)
1. Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases.
Franzese C; Comito T; Tripoli A; Franceschini D; Clerici E; Navarria P; Badalamenti M; D'agostino G; Loi M; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
Clin Exp Metastasis; 2020 Oct; 37(5):565-573. PubMed ID: 32556682
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.
Berkovic P; Gulyban A; Defraene G; Swenen L; Dechambre D; Nguyen PV; Jansen N; Mievis C; Lovinfosse P; Janvary L; Lambrecht M; De Meerleer G
BMC Cancer; 2020 May; 20(1):402. PubMed ID: 32384918
[TBL] [Abstract][Full Text] [Related]
4. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
Franzese C; Badalamenti M; Comito T; Franceschini D; Clerici E; Navarria P; Loi M; D'agostino G; Baldaccini D; Chiola I; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Radiother Oncol; 2020 Sep; 150():184-190. PubMed ID: 32593644
[TBL] [Abstract][Full Text] [Related]
5. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
[TBL] [Abstract][Full Text] [Related]
6. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.
Andratschke N; Alheid H; Allgäuer M; Becker G; Blanck O; Boda-Heggemann J; Brunner T; Duma M; Gerum S; Guckenberger M; Hildebrandt G; Klement RJ; Lewitzki V; Ostheimer C; Papachristofilou A; Petersen C; Schneider T; Semrau R; Wachter S; Habermehl D
BMC Cancer; 2018 Mar; 18(1):283. PubMed ID: 29534687
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy (SBRT) in Pelvic Lymph Node Oligometastases.
Reshko LB; Richardson MK; Spencer K; Kersh CR
Cancer Invest; 2020 Nov; 38(10):599-607. PubMed ID: 32715780
[TBL] [Abstract][Full Text] [Related]
8. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
10. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Nicosia L; Franzese C; Mazzola R; Franceschini D; Rigo M; D'agostino G; Corradini S; Alongi F; Scorsetti M
Strahlenther Onkol; 2020 Mar; 196(3):213-221. PubMed ID: 31559480
[TBL] [Abstract][Full Text] [Related]
11. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
12. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy of Lymph Node Oligometastases.
Burkoň P; Oberreiterová S; Kazda T; Slávik M; Bobek L; Komínek L; Procházka T; Vrzal M; Šlampa P
Klin Onkol; 2020; 33(2):114-122. PubMed ID: 32303132
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.
Scorsetti M; Comito T; Clerici E; Franzese C; Tozzi A; Iftode C; Di Brina L; Navarria P; Mancosu P; Reggiori G; Fogliata A; Tomatis S; Torzilli G; Cozzi L
Radiat Oncol; 2018 Nov; 13(1):234. PubMed ID: 30477560
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
18. Locoregional control and survival after lymph node SBRT in oligometastatic disease.
Loi M; Frelinghuysen M; Klass ND; Oomen-De Hoop E; Granton PV; Aerts J; Verhoef C; Nuyttens J
Clin Exp Metastasis; 2018 Oct; 35(7):625-633. PubMed ID: 29995254
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
20. Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.
Franceschini D; Franzese C; Comito T; Ilieva MB; Spoto R; Marzo AM; Dominici L; Massaro M; Bellu L; Badalamenti M; Mancosu P; Scorsetti M
Radiother Oncol; 2024 Jun; 195():110240. PubMed ID: 38522597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
